Lupus Anticoagulant

Also written as LA.

ting times will determine if repeated doses are required bleeding has also been reported in lupus anticoagulant; it

What our notes say

• ting times will determine if repeated doses are required bleeding has also been reported in lupus anticoagulant; it (Harrisons Pulmonary and Critical Care Medicine)
• These patients may have underlying thrombo disease that results from parenchymal and vascular philic disorders, such as the lupus anticoagulant/anticar remodeling. (Harrisons Cardiovascular Medicine 2nd Edition 2)
• Immunological (5–10%): Antiphospholipid syndrome (lupus anticoagulant, anticardiolipin antibodies), alloimmune factors (Abortion and miscarriage)
• Antiphospholipid syndrome (about 15%): lupus anticoagulant, anticardiolipin and anti-β2 glycoprotein antibodies on two occasions 12 weeks apart. (Abortion and miscarriage)
• | Acquired factor inhibitor | Unexpected bleeding on anticoagulant therapy, lupus anticoagulant, postpartum | Mixing study fails to correct PT/aPTT, presence of inhibitor titers | (Coagulation disorders)
• | Activated partial thromboplastin time (aPTT) | Intrinsic pathway (VIII, IX, XI, XII) & common pathway | Prolonged → hemophilia, lupus anticoagulant, heparin effect | (Coagulation disorders)

Study material on Lupus Anticoagulant

• Harrisons Pulmonary and Critical Care Medicine
• Hypercoagulable state (1)
• Abortion and miscarriage

Related topics

• Magnetic Resonance Angiography
• Antiphospholipid Syndrome
• Direct Thrombin Inhibitors
• Pulseless Electrical Activity
• Pulseless Ventricular Tachycardia
• Randomised Controlled Trial
• Critical Care Medicine
• Solid Organ Transplantation
• Positron Emission Tomography
• Sudden Infant Death Syndrome